Expanding possibilities in the treatment of patient groups with previously difficult-to-treat patients.
Dörner
Thomas
T
Burmester
Gerd R
GR
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D003240:Connective Tissue Diseases / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D004351:Drug Resistance / Q000502:physiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007155:Immunologic Factors